Back to search

Netherlands· NL-704e1120a588

Rotigotine Medical Valley 8 mg/24 uur pleister voor transdermaal gebruik

A rotigotine product containing rotigotine, registered in Netherlands by Medical Valley Invest AB. The same ATC class is registered in 18 of our 19 countries.

ATC N04BC09

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRotigotine Medical Valley 8 mg/24 uur…ATCN04BC09REGISTER NO.NL-704e1120a588PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Rotigotine is registered in 18 of 19 countries.

Countries holding a registration under ATC N04BC09 (rotigotine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose

Rotigotine · ATC N04BC09

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rotigotine costs, country by country.

Normalised to the WHO defined daily dose (6 mg), the median price runs from $0.77 in Czechia to $4.34 in Switzerland — a ×5.6 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Rotigotine · price per daily dose (6 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$4.34
  • CZ Czechia$0.77
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ROTIGOTINE
Manufacturer
Medical Valley Invest AB
Country
Netherlands (NL)
ATC code
N04BC09
ATC class
Rotigotine
Defined daily dose
6 mg, TD
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    133403

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

58 interactions on record for rotigotine.

Graded by severity as the source publishes them — 58 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rotigotine · interactions on record

58 records

  • 58 moderate

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • ThiethylperazinA04AB03moderate
  • DiphenhydraminA04AB05moderate
  • DronabinolA04AD10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rotigotine in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rotigotine products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Kinparlev, Rotigotin Gebro
  • Germany · Rotigotin Luye, Rotigotin Neuraxpharm
  • Denmark · Kinparlev, Rotigotine Medical Valley
  • Spain · Dariante
  • Finland · Kinparlev, Rotigotine Medical Valley
  • France · Rotigotine Arrow
  • Greece · Kinparlev
  • Iceland · Neupro, Rotigotine Medical Valley
  • Italy · Rotigotina Doc
  • Liechtenstein · Neupro
  • Luxembourg · Rotigotin Luye
  • Norway · Kinparlev, Neupro
  • Portugal · Kinparlev, Rotigotina Generis
  • Romania · Kinparlev
  • Sweden · Kinparlev, Rotigotine Medical Valley

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c434056f-cd8f-486e-8d2b-6d1cb5402b5c
GET /v1/drugs/c434056f-cd8f-486e-8d2b-6d1cb5402b5c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Pleister voor transdermaal gebruik",
  "route": "Transdermaal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h133403_smpc.pdf",
  "strength": null,
  "atc_label": "Rotigotine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg133403",
  "excipients": [
    "ORANJE INKT",
    "PARAFFINE, VLOEIBAAR (E905)",
    "POLYESTERFILM, GEFLUORIDEERD",
    "POLYESTERFOLIE BEKLEED MET GEPIGMENTEERD POLYETHYLEEN, THERMOPLASTISCH POLYMEER EN ALLUMINIUM",
    "POVIDON K 90 (E 1201)",
    "SILICONEN KLEEFSTOF BIO-PSA SRS7-4501",
    "SILICONEN KLEEFSTOF BIO-PSA SRS7-4601",
    "TOCOFEROL, DL-ALFA (E 307)"
  ],
  "substances": [
    "ROTIGOTINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h133403.pdf",
  "authorised_at": "2024/09/06",
  "procedure_number": "DE/H/7400/006",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "133403",
  "additional_monitoring": "N"
}

See everything about rotigotine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.